423 related articles for article (PubMed ID: 22086865)
1. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
2. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
3. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
4. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
5. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
6. Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2023 May; 98(5):801-821. PubMed ID: 36680511
[TBL] [Abstract][Full Text] [Related]
7. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
[TBL] [Abstract][Full Text] [Related]
8. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
10. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
Gangat N; Caramazza D; Vaidya R; George G; Begna K; Schwager S; Van Dyke D; Hanson C; Wu W; Pardanani A; Cervantes F; Passamonti F; Tefferi A
J Clin Oncol; 2011 Feb; 29(4):392-7. PubMed ID: 21149668
[TBL] [Abstract][Full Text] [Related]
11. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
[TBL] [Abstract][Full Text] [Related]
12. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia: 2013 update on risk-stratification and management.
Estey EH
Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
[TBL] [Abstract][Full Text] [Related]
14. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
15. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.
Caramazza D; Begna KH; Gangat N; Vaidya R; Siragusa S; Van Dyke DL; Hanson C; Pardanani A; Tefferi A
Leukemia; 2011 Jan; 25(1):82-8. PubMed ID: 20944670
[TBL] [Abstract][Full Text] [Related]
16. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2013 Nov; 88(11):967-74. PubMed ID: 23963888
[TBL] [Abstract][Full Text] [Related]
17. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of Primary Myelofibrosis in the Genomic Era.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
[TBL] [Abstract][Full Text] [Related]
19. Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis.
Bae E; Park CJ; Cho YU; Seo EJ; Chi HS; Jang S; Lee KH; Lee JH; Lee JH; Suh JJ; Im HJ
Int J Lab Hematol; 2013 Dec; 35(6):629-36. PubMed ID: 23693053
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]